Navigation Links
FDA Approves New Skin Cancer Drug First Tested in Arizona by Scottsdale Healthcare and TGen
Date:2/1/2012

SCOTTSDALE, Ariz., Feb. 1, 2012 /PRNewswire-USNewswire/ -- A new skin cancer drug tested for the first time in the world five years ago at the Virginia G. Piper Cancer Center at Scottsdale Healthcare just received expedited approval by the U.S. Food and Drug Administration, a remarkable accomplishment in new drug development.

(Photo: http://photos.prnewswire.com/prnh/20120201/DC45876)

Vismodegib (GDC-0449) was administered for the first time in the world Jan. 23, 2007 in a phase I clinical trial at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with the Translational Genomics Research Institute (TGen). Vismodegib received FDA approval on Jan. 30, 2012. Clinical trials progress through three phases and can take up to 10 years or more to successfully complete.

The drug is the first to receive FDA approval to treat inoperable basal cell carcinoma. Successful early trial results led to a broader subsequent study sponsored by Genentech. Continued positive study results led to Monday's FDA approval for marketing the drug under the name Erivedge.

Vismodegib is used to treat adult patients with advanced basal cell carcinoma, the most common type of skin cancer. It is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body (metastatic), according to the FDA.

Arizona has one of the highest incidences of skin cancer in the world, and in the United States two million new cases of basal cell carcinoma are diagnosed every year. Most instances of basal cell cancer can be effectively treated, but in some cases, the cancer cells spread and develop an aggressive form of the cancer that does not respond to standard surgical treatment.

"Until now, we did not have any treatments that can effectively slow the t
'/>"/>

SOURCE Scottsdale Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014   LabStyle Innovations ... Solution, today announced the appointment of Professor ... of its Board of Directors. Prof. ... business experience to LabStyle as an entrepreneur, venture ... and corporate governance expert. He currently serves on ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... --  Empire Genomics today announced that it has ... portfolio for the Japanese market.  The deal represents Empire,s international ... "We are excited to have such a proven and expert ... access to our broad genomic product and service portfolio," said ...
... MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. ... Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ... mg, 15 mg, and 20 mg. This product is the ... which is indicated for the treatment of schizophrenia and the ...
Cached Medicine Technology:Empire Genomics Chooses Funakoshi as Japan Distributor 2Mylan Launches Generic Version of Zyprexa® Tablets 2
(Date:7/10/2014)... New York City, NY (PRWEB) July 10, 2014 ... to the life sciences industry, has launched a new ... mobile responsiveness, as well as increased access to the ... “The new cbpartners.com provides an ideal platform to showcase ... global health access issues,” says CBPartners’ Chief Executive Officer, ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 ... the latest results of the 4th “Trending in ... suite model. , Every day multinational corporations ... contracts, expense forms etc. To meet this challenge, ... (S2P) suites which can be defined as a ...
(Date:7/10/2014)... -- Adults with dyslexia are more likely to report ... than people who don,t have the learning disorder, according ... up to 10 percent of people, causes problems with ... adults with this condition said they suffered physical abuse ... without dyslexia. "Even after accounting for age, race, ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, 2014 ... use of calorie information on menus, if it,s available, to ... U.S. study. Women in particular review the menu labeling, ... with the U.S. Centers for Disease Control and Prevention. ... to help choose their meal, compared with just under half ...
(Date:7/10/2014)... the amount of alcoholic beverages consumed, even for ... reduced risk of coronary heart disease, lower body ... a new multi-center study published in The ... of Medicine at the University of Pennsylvania. The ... suggest that consuming light-to-moderate amounts of alcohol (0.6-0.8 ...
Breaking Medicine News(10 mins):Health News:CBPartners Announces New Website 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:New study shows drinking alcohol provides no heart health benefit 2
... March 26 The statement below is attributable ... Association. This statement is being issued in response to ... England Journal of Medicine about prostate-specific antigen ... great interest the coverage surrounding the two studies about ...
... Percent of Surveyed MCO Pharmacy Directors Say They ... Idiopathic Arthritis and Pediatric Crohn,s Disease, According to ... 26 Decision Resources, one of the world,s ... healthcare issues, finds that 30 percent of surveyed ...
... radicals, researchers say , , THURSDAY, March 26 (HealthDay ... children,s lung growth and function, as well as ... University of Southern California researchers. , "Many factors ... variation and environmental exposures such as tobacco smoke ...
... (ASCTA) is formed in response to the Food and Drug Administration,s ... body are drugs, a position the ASCTA opposes. This physician ... adult stem cell therapy to their patients more quickly. , ... ...
... Strategic Cost Management Expertise with Hospitals Nationwide to Help ... An exclusive group of hospital CEOs from ... to Texas, and California to the Carolinas, will convene ... summit to address the implications of the economic stimulus ...
... March 26 Birner Dental Management Services, Inc. ... of PERFECT TEETH dental practices, ... Total dental group practice revenue decreased $371,000, or .6%, ... to $34.5 million. The Company,s earnings before interest, taxes, ...
Cached Medicine News:Health News:American Urological Association Statement in Support of Prostate-Specific Antigen Testing 2Health News:American Urological Association Statement in Support of Prostate-Specific Antigen Testing 3Health News:As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis 2Health News:As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis 3Health News:Genes May Boost Harm to Kids From Secondhand Smoke 2Health News:Physician Group Opposes FDA's Position on Adult Stem Cells 2Health News:Physician Group Opposes FDA's Position on Adult Stem Cells 3Health News:Healthcare CEO Summit Addressing Strategic Implications of Economic Stimulus Package to be Hosted by InfoLogix 2Health News:Healthcare CEO Summit Addressing Strategic Implications of Economic Stimulus Package to be Hosted by InfoLogix 3Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 2Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 3Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 4Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 5Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 6Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 7Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 8Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 9
... endoscope is the first Video ... instrument incorporates a 2.0mm instrument ... insertion tube. The slim size ... easy introduction even through areas ...
... Used for temporary internal drainage from ... Supplied sterile in peel-open packages. Intended ... is advised; C-Flex® and Sof-Flex® stents ... six (6) months; silicone stents must ...
... internal drainage from the ureteropelvic junction to ... for ease of placement and patient compliance. ... for repositioning and ease of removal. AQ® ... that when activated, attracts and holds water ...
... Double Pigtail Ureteral Stents have an ... maximizes migration. They also feature unique ... cost savings. Each Classic Double PigTail ... Double PigTail Ureteral Stent with attached ...
Medicine Products: